 |
 |  |
        |
 The company uses a proprietary technology platform to discover small molecules targeting cell signaling pathways that are dysregulated in pathological states. This research has led to the discovery of a new class of drugs called the thiazolides. The first thiazolide, nitazoxanide, is already commercialized in the United States. Other new compounds and uses are being developed as part of a collaborative research program with Stanford University. |
 |
 |
||